HOPE MANNING: Open Payments
NPI 1477028793 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,213 in 46 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $115 · 2025 $1,213
Food & beverage: $763Consulting: $450
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $600 |
| ABBVIE INC. | 14 | $196 |
| Supernus Pharmaceuticals, Inc. | 9 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| Indivior Inc. | 3 | $52 |
| Bausch Health US, LLC | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: VIVITROL, VRAYLAR, Qelbree, REXULTI, SUBLOCADE, ARISTADA, ABILIFY ASIMTUFII, Jornay PM.
Industry payments across CO — which companies pay providers there.
